Impact of Neoadjuvant Sunitinib Treatment on Tumour Thrombi in the Inferior Vena Cava in Metastatic Renal Cell Carcinoma
| Autor: | Tibor Flaskó, Csaba Berczi, Balazs Juhasz, Akos Berczi, Tamás Szerafin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Cultural Studies
medicine.medical_specialty lcsh:Internal medicine lcsh:Specialties of internal medicine metastatic renal cancer lcsh:Medicine urologic and male genital diseases lcsh:RC870-923 Inferior vena cava lcsh:RC254-282 Renal cell carcinoma lcsh:RC581-951 medicine cardiovascular diseases lcsh:RC31-1245 neoadjuvant sunitinib tumour thrombus Sunitinib business.industry lcsh:R Religious studies medicine.disease lcsh:Diseases of the genitourinary system. Urology lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.vein cardiovascular system Radiology business inferior vena cava medicine.drug radical nephrectomy |
| Zdroj: | Üroonkoloji Bülteni, Vol 19, Iss 3, Pp 162-164 (2020) |
| ISSN: | 2147-2122 |
| Popis: | The authors report cases of metastatic renal cell carcinoma with level III-IV tumour thrombi in the inferior vena cava (IVC). Cases were treated with three courses of neoadjuvant sunitinib to reduce the thrombus level before surgery. Nephrectomy and tumour thrombectomy were performed, and sunitinib treatment continued after the operation. Cases 1 and 3 showed regression of lung metastases, but the size of the primary renal tumour and thrombus remained the same. The progression-free survival of the cases was 35 months and 24 months, respectively. In case 2, the primary renal tumour, metastases and thrombus showed regression. The upper limit of the thrombus decreased by 3 cm. In this case, the progression-free survival was 15 months, and the cancer-specific survival was 18 months. The neoadjuvant sunitinib treatment had a limited effect on downsizing the extent of tumour thrombi in the IVC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|